TW202346601A - 密碼子優化的編碼b-結構域缺失的凝血因子viii蛋白的核酸及其用途 - Google Patents

密碼子優化的編碼b-結構域缺失的凝血因子viii蛋白的核酸及其用途 Download PDF

Info

Publication number
TW202346601A
TW202346601A TW112114534A TW112114534A TW202346601A TW 202346601 A TW202346601 A TW 202346601A TW 112114534 A TW112114534 A TW 112114534A TW 112114534 A TW112114534 A TW 112114534A TW 202346601 A TW202346601 A TW 202346601A
Authority
TW
Taiwan
Prior art keywords
fviii
aav
bdd
nucleic acid
seq
Prior art date
Application number
TW112114534A
Other languages
English (en)
Chinese (zh)
Inventor
塔提安娜 蘇嘉瓦
艾琳娜 弗拉索
安娜西亞 佛米那
瑪利亞 佩瑞佩
安娜 史翠寇法
保羅 葛后菲
帕維爾 埃科里
狄密崔 摩羅佐
Original Assignee
俄羅斯聯邦商拜奧卡德聯合股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2022111734A external-priority patent/RU2808564C2/ru
Application filed by 俄羅斯聯邦商拜奧卡德聯合股份公司 filed Critical 俄羅斯聯邦商拜奧卡德聯合股份公司
Publication of TW202346601A publication Critical patent/TW202346601A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW112114534A 2022-04-28 2023-04-19 密碼子優化的編碼b-結構域缺失的凝血因子viii蛋白的核酸及其用途 TW202346601A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RURU2022111734 2022-04-28
RU2022111734A RU2808564C2 (ru) 2022-04-28 Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови VIII c делетированным B доменом, и ее применение

Publications (1)

Publication Number Publication Date
TW202346601A true TW202346601A (zh) 2023-12-01

Family

ID=88482201

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112114534A TW202346601A (zh) 2022-04-28 2023-04-19 密碼子優化的編碼b-結構域缺失的凝血因子viii蛋白的核酸及其用途

Country Status (20)

Country Link
US (1) US20250282847A1 (cg-RX-API-DMAC7.html)
EP (1) EP4514836A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025514313A (cg-RX-API-DMAC7.html)
KR (1) KR20250007615A (cg-RX-API-DMAC7.html)
CN (1) CN116970629A (cg-RX-API-DMAC7.html)
AR (1) AR129163A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023261338A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250665A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003296A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024014690A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240524A (cg-RX-API-DMAC7.html)
IL (1) IL316584A (cg-RX-API-DMAC7.html)
JO (1) JOP20240241A1 (cg-RX-API-DMAC7.html)
MA (1) MA68586A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013280A (cg-RX-API-DMAC7.html)
PE (1) PE20251838A1 (cg-RX-API-DMAC7.html)
PY (1) PY2331315A (cg-RX-API-DMAC7.html)
TW (1) TW202346601A (cg-RX-API-DMAC7.html)
UY (1) UY40241A (cg-RX-API-DMAC7.html)
WO (1) WO2023211316A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
CN108884145B (zh) * 2015-11-13 2023-08-22 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
CN113226352B (zh) * 2018-08-24 2025-08-26 星火治疗有限公司 最优化启动子序列、无内含子的表达结构及使用方法

Also Published As

Publication number Publication date
US20250282847A1 (en) 2025-09-11
KR20250007615A (ko) 2025-01-14
CR20240524A (es) 2025-05-05
JP2025514313A (ja) 2025-05-02
UY40241A (es) 2023-10-13
CL2024003296A1 (es) 2025-02-21
WO2023211316A1 (en) 2023-11-02
JOP20240241A1 (ar) 2024-10-27
MA68586A1 (fr) 2025-04-30
CA3250665A1 (en) 2023-11-02
EP4514836A1 (en) 2025-03-05
IL316584A (en) 2024-12-01
PE20251838A1 (es) 2025-07-17
CN116970629A (zh) 2023-10-31
AU2023261338A1 (en) 2024-11-21
CO2024014690A2 (es) 2025-03-06
AR129163A1 (es) 2024-07-24
MX2024013280A (es) 2024-12-06
PY2331315A (es) 2023-10-31

Similar Documents

Publication Publication Date Title
CN101511373B (zh) 用于基因治疗的修饰的因子ⅷ和因子ⅸ基因和载体
US20220396611A1 (en) Factor viii construct
CN116949052A (zh) 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
TW202342751A (zh) 編碼基於fviii-bdd和異源信號肽的融合蛋白的分離的核酸及其用途
US20250282847A1 (en) Codon-optimized nucleic acid encoding the fviii-bdd
HK40095429A (en) Codon-optimized nucleic acid encoding the b-domain deleted coagulation factor viii protein and its use
EA050470B1 (ru) Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови viii c делетированным b доменом
HK40105215A (en) Isolated nucleic acid that encodes fusion protein based on fviii-bdd and on heterologous signal peptide, and use thereof
OA22108A (en) Codon-Optimized Nucleic Acid Encoding The Fviii-Bdd.
OA22146A (en) Isolated Nucleic Acid That Encodes Fusion Protein Based On Fviii-Bdd And On Heterologous Signal Peptide.
EA052355B1 (ru) Выделенная нуклеиновая кислота, которая кодирует слитый белок на основе fviii-bdd и гетерологичного сигнального пептида
US20210395714A1 (en) Modified factor ix polypeptides
US12583907B2 (en) Modified plasma clotting factor VIII and method of use thereof
RU2808564C2 (ru) Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови VIII c делетированным B доменом, и ее применение
RU2831751C2 (ru) Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови IX, и ее применение
US20240076691A1 (en) Codon-optimized nucleic acid encoding the fix protein
US20250281640A1 (en) Nucleic acid having promoter activity and use thereof
EA048549B1 (ru) Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови ix, и ее применение
OA22010A (en) Nucleic Acid Having Promoter Activity And Use Thereof.
WO2022211791A1 (en) Modified plasma clotting factor viii and method of use thereof